StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
20
This month
1
This year
2
Publishing Date
2024 - 04 - 16
1
2024 - 02 - 05
1
2023 - 12 - 05
1
2023 - 11 - 27
1
2023 - 10 - 03
1
2023 - 03 - 06
1
2022 - 09 - 20
1
2022 - 08 - 18
1
2022 - 08 - 10
1
2022 - 07 - 25
1
2022 - 06 - 27
1
2022 - 05 - 20
1
2021 - 12 - 21
1
2021 - 10 - 07
1
2021 - 09 - 15
1
2021 - 06 - 01
1
2021 - 04 - 13
3
2020 - 12 - 01
1
Sector
Health technology
20
Professional, scientific, and technical services
1
Tags
Achondroplasia
1
Alliances
3
Announces collaboration
1
Application
3
Approval
1
Authorization
2
Bbp-631
1
Bbp-671
1
Bbp-812
1
Biotech-bay
1
Biotech-beach
1
Cancer
2
Ceo
1
Change
1
China
1
Chmp
1
Clinical-trials-phase-i
1
Collaboration
3
Designation
3
Disease
1
Drug
3
Events
1
Fast track
2
Fast track designation
2
Fda
3
Fda acceptance
1
Fda fast track
2
Fda-approvals
1
Food
2
For
1
Genetic
3
Innovation
1
Israel
1
Lung cancer
1
Multi-year
1
N/a
10
New drug
1
Nulibry
5
Partnership
1
Pharma
11
Phase 2
1
Positive
3
Potential
3
Pre-clinical
1
Preclinical
1
Ptr-01
1
Rare
1
Research
2
Results
1
Submission
1
Therapeutics
4
Therapy
3
Treatment
18
Trial
2
Velocity
1
Entities
3m company
21
Abbott laboratories
62
Abbvie inc.
121
Accuray incorporated
21
Adamis pharmaceuticals corporation
19
Adial pharmaceuticals, inc
22
Alnylam pharmaceuticals, inc.
38
Amgen inc.
47
Arcutis biotherapeutics, inc.
25
Arrowhead pharmaceuticals, inc.
22
Astellas pharma inc
52
Astrazeneca plc
52
Bausch health companies inc.
36
Biogen inc.
42
Biohaven pharmaceutical holding company ltd.
19
Bioxcel therapeutics, inc.
20
Boston scientific corporation
21
Brainsway ltd.
41
Bridgebio pharma, inc.
20
Bristol-myers squibb company
94
Cns pharmaceuticals, inc.
26
Coherus biosciences, inc.
28
Compass pathways plc
20
Ecolab inc.
47
Eli lilly and company
180
Fortress biotech, inc.
27
Gilead sciences, inc.
50
Glaxosmithkline plc
103
Hoth therapeutics, inc.
24
Incyte corporation
77
Intellia therapeutics, inc.
32
Jazz pharmaceuticals plc
20
Johnson & johnson
211
Karyopharm therapeutics inc.
33
Koninklijke philips n.v.
21
Medicinova, inc.
24
Medtronic plc
46
Merck & company, inc.
66
Moleculin biotech, inc.
28
Novartis ag
145
Novo nordisk a/s
37
Nrx pharmaceuticals inc
20
Orange
87
Perrigo company
23
Pfizer, inc.
75
Reata pharmaceuticals, inc.
28
Regeneron pharmaceuticals, inc.
58
Regenxbio inc.
25
Sanofi
299
Sorrento therapeutics, inc.
37
Takeda pharmaceutical company limited
55
Teleflex incorporated
21
Teva pharmaceutical industries ltd
79
Tg therapeutics, inc.
24
Tonix pharmaceuticals holding corp.
32
Ultragenyx pharmaceutical inc.
25
Verrica pharmaceuticals inc.
23
Vertex pharmaceuticals incorporated
27
Viatris inc.
46
Xylem inc.
35
Symbols
BBIO
20
JNJ
1
LIAN
1
Exchanges
Nasdaq
20
Nyse
1
Crawled Date
2024 - 04 - 16
1
2024 - 02 - 05
1
2023 - 12 - 05
1
2023 - 11 - 27
1
2023 - 10 - 03
1
2023 - 03 - 06
1
2022 - 09 - 20
1
2022 - 08 - 18
1
2022 - 08 - 10
1
2022 - 07 - 25
1
2022 - 06 - 27
1
2022 - 05 - 20
1
2021 - 12 - 21
1
2021 - 10 - 07
1
2021 - 09 - 15
1
2021 - 06 - 01
1
2021 - 04 - 13
3
2020 - 12 - 01
1
Crawled Time
12:00
10
12:20
1
12:30
2
13:00
1
13:30
2
15:00
1
16:00
1
22:00
1
22:02
1
Source
bridgebio.com
3
www.biospace.com
10
www.globenewswire.com
5
www.prnewswire.com
2
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
treatment
entities :
Bridgebio pharma, inc.
save search
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain
Published:
2024-04-16
(Crawled : 16:00)
- biospace.com/
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
-2.87%
|
O:
-1.47%
H:
2.05%
C:
-0.59%
nulibry
authorization
treatment
for
therapeutics
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Published:
2024-02-05
(Crawled : 12:30)
- bridgebio.com
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
-26.19%
|
O:
-1.21%
H:
1.43%
C:
0.39%
pharma
drug
food
treatment
application
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Published:
2023-12-05
(Crawled : 12:30)
- bridgebio.com
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
-21.63%
|
O:
-0.75%
H:
1.58%
C:
-0.32%
pharma
drug
food
treatment
application
submission
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD
Published:
2023-11-27
(Crawled : 13:30)
- prnewswire.com
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-2.1%
|
O:
0.64%
H:
0.02%
C:
-0.66%
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
-15.38%
|
O:
-0.2%
H:
2.17%
C:
0.91%
ceo
change
treatment
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
Published:
2023-10-03
(Crawled : 12:00)
- bridgebio.com
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
-1.5%
|
O:
0.0%
H:
1.4%
C:
0.08%
bbp-631
partnership
multi-year
bbp-812
therapy
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
Published:
2023-03-06
(Crawled : 12:00)
- globenewswire.com
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
130.27%
|
O:
65.5%
H:
7.78%
C:
-8.17%
velocity
positive
results
achondroplasia
phase 2
BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Published:
2022-09-20
(Crawled : 13:00)
- biospace.com/
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
121.9%
|
O:
-0.09%
H:
4.17%
C:
2.13%
nulibry
treatment
pharma
therapeutics
authorization
BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)
Published:
2022-08-18
(Crawled : 12:20)
- biospace.com/
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
136.13%
|
O:
-0.85%
H:
2.28%
C:
1.81%
bbp-671
treatment
pharma
trial
potential
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Published:
2022-08-10
(Crawled : 12:00)
- globenewswire.com
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
125.7%
|
O:
3.97%
H:
5.9%
C:
3.99%
nulibry
treatment
pharma
israel
approval
therapeutics
BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Published:
2022-07-25
(Crawled : 12:00)
- prnewswire.com
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
146.6%
|
O:
0.59%
H:
8.42%
C:
8.03%
nulibry
treatment
pharma
chmp
therapeutics
positive
National Organization for Rare Disorders (NORD) honors NULIBRY® (fosdenopterin) for the Treatment of molybdenum cofactor deficiency (MoCD) Type A with 2022 Industry Innovation Award
Published:
2022-06-27
(Crawled : 15:00)
- biospace.com/
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
172.07%
|
O:
0.22%
H:
2.22%
C:
1.3%
nulibry
treatment
rare
innovation
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Published:
2022-05-20
(Crawled : 12:00)
- globenewswire.com
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
249.34%
|
O:
3.42%
H:
2.83%
C:
2.7%
ptr-01
treatment
pharma
trial
positive
therapy
LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China
Published:
2021-12-21
(Crawled : 13:30)
- biospace.com/
LIAN
|
$4.92
0.41%
0.41%
410K
|
Professional, Scientific, and T...
|
-35.06%
|
O:
6.24%
H:
0.13%
C:
-6.63%
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
-39.6%
|
O:
0.07%
H:
4.03%
C:
2.15%
treatment
china
BridgeBio Pharma Announces First Publication of Preclinical Data for its Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-small Cell Lung Cancer Models
Published:
2021-10-07
(Crawled : 22:00)
- biospace.com/
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
-44.27%
|
O:
0.2%
H:
3.57%
C:
-0.56%
treatment
lung cancer
potential
cancer
preclinical
pre-clinical
designation
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Published:
2021-09-15
(Crawled : 12:00)
- biospace.com/
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
-48.64%
|
O:
0.47%
H:
1.06%
C:
-1.02%
treatment
fda
fda fast track
fast track
therapy
fast track designation
designation
BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1
Published:
2021-06-01
(Crawled : 12:00)
- globenewswire.com
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
-57.72%
|
O:
0.88%
H:
1.61%
C:
1.09%
treatment
fda
fda fast track
fast track
fast track designation
designation
pharma
BridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research
Published:
2021-04-13
(Crawled : 12:00)
- globenewswire.com
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
-53.61%
|
O:
0.43%
H:
2.42%
C:
0.76%
disease
treatment
genetic
potential
collaboration
research
BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers
Published:
2021-04-13
(Crawled : 12:00)
- biospace.com/
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
-53.61%
|
O:
0.43%
H:
2.42%
C:
0.76%
treatment
genetic
cancer
collaboration
pharma
BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions
Published:
2021-04-13
(Crawled : 12:00)
- biospace.com/
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
-53.61%
|
O:
0.43%
H:
2.42%
C:
0.76%
treatment
genetic
collaboration
announces collaboration
pharma
BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma
Published:
2020-12-01
(Crawled : 22:02)
- biospace.com/
BBIO
|
$25.03
-1.69%
-1.76%
1.5M
|
Health Technology
|
-50.18%
|
O:
1.49%
H:
2.78%
C:
0.27%
fda
drug
fda acceptance
treatment
new drug
application
pharma
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4253
179.25%
64.77%
210M
|
Consumer Services
BOF
|
$2.08
77.78%
41.21%
110M
|
ILAG
|
$0.54
12.27%
40.62%
3.7M
|
LICN
|
$0.999
78.39%
40.49%
15M
|
AMST
|
$3.4
70.0%
39.58%
70M
|
Technology Services
MTC
|
$3.6
60.71%
38.04%
9.1M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.458
14.5%
30.92%
91K
|
Health Services
WHLM
|
$6.25
35.87%
28.46%
700K
|
Commercial Services
MULN
|
News
|
$3.77
38.1%
27.78%
13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.